BACE1, the essential and exclusive APP-cleaving enzyme generating Aβ [3,41,42], and increased BACE1 in AD brains, plays a critical role in AD pathophysiology [46], thus implying that BACE1 might be an important drug target for slowing Aβ production in early AD. The gene discussed is BACE1; the disease is Alzheimer disease.